SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021)

• Ana Fernández-Montes ^[1] ; Julia Alcaide ^[7] ; María Alsina ^[8] ; Ana Belén Custodio ^[2] ; Lourdes Fernández Franco ^[3] ; Javier Gallego Plazas ^[4] ; Carlos Gómez-Martín ^[9] ; Paula Richart ^[10] ; Fernando Rivera ^[5] ; Marta Martin-Richard ^[6]
  1. [1] Complexo Hospitalario Universitario de Ourense

     Complexo Hospitalario Universitario de Ourense

     Ourense, España

     
  2. [2] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  3. [3] Hospital Virgen de la Salud

     Hospital Virgen de la Salud

     Toledo, España

     
  4. [4] Hospital General Universitario de Elche

     Hospital General Universitario de Elche

     Elche, España

     
  5. [5] Hospital Universitario Marqués de Valdecilla

     Hospital Universitario Marqués de Valdecilla

     Santander, España

     
  6. [6] Hospital Duran i Reynals

     Hospital Duran i Reynals

     Barcelona, España

     
  7. [7] Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain
  8. [8] Medical Oncology Department, Hospital Universitario de Navarra (HUN), Pamplona, Spain Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
  9. [9] Gastrointestinal Cancer Unit, Medical Oncology Division, Doce de Octubre University Hospital, Madrid, Spain
  10. [10] Medical Oncology Department, Hospital Universitari I Politècnic la Fe, Valencia, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 4 (April), 2022, págs. 658-669
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Esophageal cancer is an aggressive tumor, and is the sixth-leading cause of death from cancer. Incidence is rising in Spain, particularly among men. Two main pathological different subtypes have been described: squamous cell carcinoma and adenocarcinoma. Growing evidence of their epidemiology and molecular differences explains their different response to novel treatments, and they are therefore likely to be treated as two separate entities in the near future. The best results are obtained with a multidisciplinary therapeutic strategy, and the introduction of immunotherapy is a promising new approach that will improve prognosis. In these guidelines, we review the evidence for the different methods of diagnosis and therapeutic strategies that form the basis of our standard of care.